Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Listed in Dosage.
|
|
Dosage/Direction for Use
Adult: SC Prevention of severe thrombocytopenia after myelosuppressive chemotherapy; Reduce the need for platelet transfusions after myelosuppressive chemotherapy 50 mcg/kg/day. Give initial dose 6-24 hr after the last antineoplastic dose and continue for up to a max of 21 days. Discontinue at least 2 days before the next chemotherapy cycle.
|
|
Contraindications
Do not use after myeloablative chemotherapy and bone marrow transplantation.
|
|
Special Precautions
History or signs of heart failure. Monitor fluid and electrolyte balance in patients on prolonged diuretic therapy. Pre-existing papilloedema or CNS tumours, pre-existing pericardial effusions or ascites. Hepatic, renal or respiratory impairment. History of stroke or thromboembolic disorders. Pregnancy and lactation.
|
|
Adverse Reactions
Tachycardia, oedema, palpitation, cardiomegaly, vasodilation, syncope, atrial arrhythmia; headache, dizziness, fever, insomnia, fatigue; rash; fluid retention; nausea/vomiting, diarrhoea, oral moniliasis; dilutional anaemia; weakness, arthralgia, periostitis; conjunctival inj/redness/swelling, papilloedema; dyspnoea, rhinitis, cough, pharyngitis; wt gain; pleural effusion.
Potentially Fatal: Anaphylactoid reactions. |
|
Drug Interactions
Increased risk of adverse CV effects with diuretics (due to hypokalaemia).
|
|
CIMS Class
|
|
ATC Classification
L03AC02 - oprelvekin ; Belongs to the class of interleukins. Used as immunostimulants.
|
